Head-To-Head Review: Enliven Therapeutics (NASDAQ:ELVN) vs. Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals (NASDAQ:RVPH) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Institutional & Insider Ownership

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 8.9% of Reviva Pharmaceuticals shares are held by insiders. Comparatively, 25.9% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for Reviva Pharmaceuticals and Enliven Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1	0	7	1	2.89
Enliven Therapeutics	1	0	5	0	2.67

Reviva Pharmaceuticals currently has a consensus target price of $3.86, suggesting a potential upside of 525.45%. Enliven Therapeutics has a consensus target price of $41.20, suggesting a potential upside of 107.56%. Given Reviva Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe Reviva Pharmaceuticals is more favorable than Enliven Therapeutics.

Profitability

This table compares Reviva Pharmaceuticals and Enliven Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-20,501.80%	-187.50%
Enliven Therapeutics	N/A	-24.88%	-23.96%

Valuation and Earnings

This table compares Reviva Pharmaceuticals and Enliven Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$29.92 million	($0.46)	-1.34
Enliven Therapeutics	N/A	N/A	-$89.02 million	($1.84)	-10.79

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Reviva Pharmaceuticals has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.

Summary

Reviva Pharmaceuticals beats Enliven Therapeutics on 7 of the 12 factors compared between the two stocks.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.